Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells.

Journal of molecular medicine (Berlin, Germany) - 1 Aug 2008

Bremer Edwin, de Bruyn Marco, Samplonius Douwe F, Bijma Theo, ten Cate Bram, de Leij Lou F M H, Helfrich Wijnand

Abstract excerpt

Previously, we have shown that epidermal growth factor receptor (EGFR)-selective delivery of soluble tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL), by genetic fusion to antibody fragment scFv425, enhances the tumor-selective pro-apoptotic activity of sTRAIL. Insight into the re...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to ErbB Receptors
Share to Gene Transfer Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Jurkat Cells

Share to Ligands

Share to Receptors, TNF-Related Apoptosis-Inducing Ligand

Share to Recombinant Fusion Proteins

Share to TNF-Related Apoptosis-Inducing Ligand

Source

Open in PubMed Open full text

Identifiers

PMID: 18504532
DOI: 10.1007/s00109-008-0348-9
PMCID: PMC2491411

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18504532-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells.PMID 18504532Read ↗

CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants.Semantic proximity Read ↗

Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.Semantic proximity Read ↗

The TRAIL of oncogenes to apoptosisSemantic proximity Read ↗

APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Efficacy Independent of Cross-Linking via Fcγ ReceptorsSemantic proximity Read ↗

DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.Semantic proximity Read ↗

TRAIL as a target in anti-cancer therapy.Semantic proximity Read ↗

The TRAIL apoptotic pathway in cancer onset, progression and therapy.Semantic proximity Read ↗

Generation of a novel TRAIL mutant by proline to arginine substitution based on codon bias and its antitumor effects.Semantic proximity Read ↗

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling.Semantic proximity Read ↗

Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.Semantic proximity Read ↗

DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.Semantic proximity Read ↗

Apoptosis-Inducing TNF Superfamily Ligands for Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.